Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus.
II. Evaluate objective disease parameters, including serum complement levels, anti-DNA antibody titers, sedimentation rate, and the systemic lupus activity measure in these patients.
|Study Design:||Masking: None (Open Label)
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004643
|Study Chair:||Bruce Richardson||University of Michigan|